MedTrace Logo

Sleep Assessment in CML

NCT03353558 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-11-28

No results posted yet for this study

Summary

Patients with CML report on fatigue, and many of them report on sleep disturbances. The investigators wish to objectively assess the patient's sleep using a sleep "wrist watch" (Actigraph) , and correlate data with their perception of sleep quality. A matched participants group will serve as control. the Control group is defined as participants not having CML or any other malignancy and without any known sleep disturbances.

Conditions

  • Sleep Disorder
  • Chronic Myeloid Leukemia

Interventions

DEVICE

Actigraph

The watch will measure sleep parameters like quality of sleep, time to fall asleep, number of awakenings during night, length of deep sleep.

Sponsors & Collaborators

  • The Max Stern Academic College Of Emek Yezreel

    collaborator OTHER

  • HaEmek Medical Center, Israel

    lead OTHER

Principal Investigators

  • Aviv A Ariel, Doctor · Head of hematology department

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2018-05-31
Completion
2018-12-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03353558 on ClinicalTrials.gov